TriSalus Life Sciences, an oncology therapeutics company, agreed to go public via a merger with MedTech Acquisition, a special purpose acquisition company, in a $244m deal. “We are excited to complete this merger with TriSalus and support the growth of its innovative devices and treatments. We believe that TriSalus has significant near and long-term value creation opportunities through its commercialization strategy and the potential to deploy SD-101 into multiple indications across several lines of therapy. We have full confidence that Mary and the experienced TriSalus team will continue working to meet significant unmet medical needs and delivering value to shareholders," Chris Dewey, MedTech CEO.